bioRxiv Science⌕ Search

Biology subjects

Jha, N. K.

Publications and source records attributed to Jha, N. K..

2 recordsLinked to original sources

Natural Product Screen Identifies Asiatic Acid Targeting Mutant p53

Mutations in p53 are common in different cancer types and are reported to protect cancer via different mechanisms. R175H, R248Q, and R273H are the hotspot mutations of p53 and are suggested to increase aerobic glycolysis in cancer cells. Cancer cells rely mostly upon aerobic glycolysis, so it will be interesting to target these three p53 mutants for designing alternative cancer therapy. The class of compounds studied for their potential to target energy metabolism of cancer cells is called mitocans. The current study is an approach to explore if these selected 3 mutants of p53 may act as suitable target(s) for natural mitocans. Hereby, we selected 60 phytocompounds altogether from Andrographis paniculata and Centella asiatica and docked against all three p53 mutants, using Autodock vina. 11 compounds were sorted based on their binding energies and drug-like properties, and toxicity levels prediction showed asiatic acid to be the most significant. As asiatic acid was observed to significantly bind with R248Q only, R248Q-Asiatic acid was identified for molecular dynamics simulation using GROMACS which showed significant interactions. In conclusion, mutant R248Q was observed to be the best target for asiatic acid, though additional in-vitro experiments are important to validate the findings of this study.

cancer biology↗

Towards a Chimeric Vaccine against Multiple Isolates of Mycobacteroides - An Integrative Approach

Nontuberculous mycobacterial infection (NTM) such as endophthalmitis, dacryocystitis, canaliculitis are pervasive across the globe and are currently managed by antibiotics such as cefoxitin/imipenem and azithromycin/clarithromycin. However, the recent cases of Mycobacteroides developing drug resistance reported along with the improper practice of medicine intrigued us to explore its genomic and proteomic canvas at a global scale. A timely developed vaccine against Mycobacteroides is, therefore, a much requirement. Consequently, we carried out a vivid Genomic study on five recently sequenced strains of Mycobacteroides and explored their Pan-Core genome/ proteome. The promiscuous antigenic proteins were identified via a subtractive proteomics approach that qualified for virulence causation, resistance and essentiality factors for this notorious bacterium. An integrated pipeline was developed for the identification of B Cell, MHC class I, II epitopes. Our final vaccine construct, V6 qualified for all tests such as absence for allergenicity, presence of antigenicity, etc. and contains {beta} defensin adjuvant, linkers, LAMP1 signal peptide, and PADRE (Pan HLA-DR epitopes) amino acid sequence. The vaccine construct, V6 also interacts with a maximum number of MHC molecules, and the TLR4/MD2 complex confirmed by docking and molecular dynamics simulation studies. The knowledge harnessed from the current study can help improve the current treatment regimens and propel further related studies.

bioinformatics↗